Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 160

2.
3.

Effects of vitamin E on cardiovascular and microvascular outcomes in high-risk patients with diabetes: results of the HOPE study and MICRO-HOPE substudy.

Lonn E, Yusuf S, Hoogwerf B, Pogue J, Yi Q, Zinman B, Bosch J, Dagenais G, Mann JF, Gerstein HC; HOPE Study; MICRO-HOPE Study.

Diabetes Care. 2002 Nov;25(11):1919-27.

PMID:
12401733
4.

The HOPE Study (Heart Outcomes Prevention Evaluation).

Sleight P.

J Renin Angiotensin Aldosterone Syst. 2000 Mar;1(1):18-20. Review.

PMID:
11967789
6.

Diabetes and the HOPE study: implications for macrovascular and microvascular disease.

Gerstein HC.

Int J Clin Pract Suppl. 2001 Jan;(117):8-12.

PMID:
11715357
7.

The HOPE study. Ramipril lowered cardiovascular risk, but vitamin E did not.

Hoogwerf BJ, Young JB.

Cleve Clin J Med. 2000 Apr;67(4):287-93.

PMID:
10780101
8.

Progression of renal insufficiency in type 2 diabetes with and without microalbuminuria: results of the Heart Outcomes and Prevention Evaluation (HOPE) randomized study.

Mann JF, Gerstein HC, Yi QL, Franke J, Lonn EM, Hoogwerf BJ, Rashkow A, Yusuf S; HOPE Investigators.

Am J Kidney Dis. 2003 Nov;42(5):936-42.

PMID:
14582037
9.

The non-insulin-dependent diabetes, hypertension, microalbuminuria or proteinuria, cardiovascular events, and ramipril (DIABHYCAR) study: design, organization, and patient recruitment. DIABHYCAR Study Group.

Lièvre M, Marre M, Chatellier G, Plouin P, Réglier J, Richardson L, Bugnard F, Vasmant D.

Control Clin Trials. 2000 Aug;21(4):383-96.

PMID:
10913814
10.

What should the role of ACE inhibitors be in the treatment of diabetes? Lessons from HOPE and MICRO-HOPE.

Heinig RE.

Diabetes Obes Metab. 2002 Jan;4 Suppl 1:S19-25. Review.

PMID:
11843951
11.

Why were the results of the Heart Outcomes Prevention Evaluation (HOPE) trial so astounding?

Mancini GB, Stewart DJ.

Can J Cardiol. 2001 May;17 Suppl A:15A-7A.

PMID:
11381289
13.

Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study).

Marre M, Lievre M, Chatellier G, Mann JF, Passa P, Ménard J; DIABHYCAR Study Investigators.

BMJ. 2004 Feb 28;328(7438):495. Epub 2004 Feb 11. Erratum in: BMJ. 2004 Mar 20;328(7441):686.

14.
15.

Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial.

Sacco M, Pellegrini F, Roncaglioni MC, Avanzini F, Tognoni G, Nicolucci A; PPP Collaborative Group.

Diabetes Care. 2003 Dec;26(12):3264-72.

PMID:
14633812
16.
17.

HOPE for all people with diabetes? Heart Outcomes Prevention Evaluation.

Marshall SM.

Diabet Med. 2000 Sep;17 Suppl 2:9-10. No abstract available.

PMID:
11048826
18.

Treatment of the diabetic patient: focus on cardiovascular and renal risk reduction.

Abbott KC, Bakris GL.

Prog Brain Res. 2002;139:289-98. Review.

PMID:
12436944
19.

Effect of ACE and AT-2 inhibitors on mortality and progression to microalbuminuria in a nested case-control study of diabetic nephropathy in diabetes mellitus type 2: results from the GENDIAN study.

Böger CA, Haak T, Götz AK, Christ J, Ruff E, Hoffmann U, Riegger GA, Krämer BK.

Int J Clin Pharmacol Ther. 2006 Aug;44(8):364-74.

PMID:
16961167
20.

The relationship between dysglycaemia and cardiovascular and renal risk in diabetic and non-diabetic participants in the HOPE study: a prospective epidemiological analysis.

Gerstein HC, Pogue J, Mann JF, Lonn E, Dagenais GR, McQueen M, Yusuf S; HOPE investigators.

Diabetologia. 2005 Sep;48(9):1749-55. Epub 2005 Jul 30.

PMID:
16059716

Supplemental Content

Support Center